Fat mass index (mean, SD) 27.6 (5.3) 26.6 (4.6)* 26.8 (4.4) 27.4 (3.6) % of fat distributed to the trunk (mean, SD) 52.2 (6.3) 49.4 (6.5)* 58.8 (6.4) 57.6 (5.6) Android to gynoid fat mass ratio (mean, SD) 0.5 (0.2) 0.5 (0.2) 0.7 (0.2) 0.8 (0.2)* Lean mass index (mean, SD) 6.6 (0.9) 6.7 (0.8)* 8.0 (1.1) 8.6 (1.0)* Obese (n,%) 99 (45.2) 334 (38.4) 50 (52.1) 222 (57.7) Sarcopenic (n,%) 11 (5.0) 11 (1.3)* 8 (8.2) 6 (1.5)* Sarcopenic obesity (n,%) 2 (0.9) 2 (0.2) 4 (4.2) 3 (0.8)* n = number, SD = standard deviation, % == percentages *p-value <0.05 between arthritis and non-arthritis controls.
Conclusions:
Patients at the clinical onset of arthritis more often have an unfavorable body composition (sarcopenia and sarcopenic obesity) than nonarthritis controls. An unfavorable body composition was associated with higher blood pressure and lipid levels (and lower HDL levels). Five patients received TNFi prior to ILD diagnosis (3 ETN, 1 infliximab and 1 adalimumab). Biological therapy was withdrawn in 3 cases and switched to ABA in the two remaining ones. The median duration of EPID was 2.5 (range 0.7-11.9) years. HRCT patterns were: non-specific interstitial pneumonia (NSIP) 52.9%, usual interstitial pneumonia (UIP) 17.6%, cryptogenic organized pneumonia (COP)11. 8%, and other patterns 17.7%. 14 patients had baseline and follow-up PFT: 9 (64.3%) remained stable; 3 (21.4%) improved and 2 (14.3%) worsened (1 had received previous ETN). There was a trend for worsening of PFT in patients with UIP pattern. No patient died from ILD during this period Conclusions: In our RA-ILD cohort, NSIP was the most common HRCT pattern and PFT remained stable in most patients during follow-up. Five patients (23.8%) had received TNFi prior to ILD diagnosis and only one of them showed worsening of PFT during ETN treatment, with clinical improvement after withdrawal. Background: Comorbidity is common in ethnic patients with rheumatoid arthritis (RA) and often impact choice of DMARD therapy and clinical outcomes. In addition to simple summation of comorbidities, composite indices have been proffered as better predictors of poor clinical outcomes in patients with rheumatoid arthritis 1 . However, their applicability in ethnic RA subsets is unknown. Objectives: To compare composite to mean comorbidity indices in ethnic subsets with rheumatoid arthritis. Methods: Patients enrolled in the Ethnic Minority RA Consortium (EMRAC), with at least 6 months of followup data were analyzed. At enrollment, sociodemographic data and RA disease status, rheumatic disease comorbidity index (RCDI) 1 and comorbidity count (COUNT) 1 were analyzed amongst ethnic subsets. Spearman correlation was estimated between RCDI and COUNT while Poisson regression
